Helicos Announces Order for a Helicos Genetic Analysis System from a Leading U.S. Cancer Center for Cancer Stem Cell Research
2008-08-05 06:00:00
Helicos Announces Order for a Helicos Genetic Analysis System from a Leading U.S. Cancer Center for Cancer Stem Cell Research
CAMBRIDGE, Mass.–(EMWNews)–Helicos BioSciences Corporation
(NASDAQ:HLCS) today announced that a leading U.S. cancer research center
has placed an order for a Helicos™ Genetic
Analysis System for use in a cutting-edge research program involving
cancer stem cell biology. The Helicos Genetic Analysis System was chosen
because of its unique capability of true direct DNA measurement which
provides the most unbiased view of DNA and RNA critical for stem cell
research.
About Helicos BioSciences
Helicos BioSciences is a life science company focused on innovative
genetic analysis technologies for the research, drug discovery, and
diagnostic markets. Helicos’ proprietary True Single Molecule Sequencing
(tSMS)™ technology allows direct measurement
of billions of strands of DNA, enabling scientists to perform
experiments and ask questions never before possible. Helicos is a
recipient of the $1,000 genome grant and is committed to providing
scientists the tools to unlock the era of genomic medicine. The
company’s corporate headquarters are located at One Kendall Square,
Building 700, Cambridge, MA 02139, and its telephone number is (617)
264-1800. For more information, please visit www.helicosbio.com.
Certain statements made in this press release that are not based on
historical information are forward-looking statements which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains
express or implied forward-looking statements relating to, among other
things, Helicos’ expectations concerning the fulfillment of the order
discussed in this press release and management’s plans, objectives and
strategies. These statements are neither promises nor guarantees,
but are subject to a variety of risks and uncertainties, many of which
are beyond Helicos’ control, which could cause actual results to differ
materially from those contemplated in these forward-looking statements.
In particular, the risks and uncertainties include, among other things,
our ability to successfully complete the manufacturing process and
commercialize the Helicos Genetic Analysis System; competition; changing
technology and customer requirements; our ability to operate in an
emerging market; market acceptance of our technology; our ability to
retain our personnel and hire additional skilled personnel; our ability
to manage our rapid growth and our ability to obtain capital when
desired on favorable terms. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Helicos
undertakes no obligation to update or revise the information contained
in this press release, whether as a result of new information, future
events or circumstances or otherwise. For additional disclosure
regarding these and other risks faced by Helicos, see the disclosure
contained in Helicos’ public filings with the Securities and Exchange
Commission.
|
Helicos BioSciences Corporation Relations Group Supervisor |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
